Public-registry trials using RTX-240 that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
| Trial | Sponsor | Condition | Phase | Sites |
| RTX-240 Monotherapy and in Combination With Pembrolizumab | Rubius Therapeutics | Solid Tumor, AML Adult | PHASE1 / PHASE2 | 11 |
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →